A life-span inventory of sports participation and Zuckerman's (1979) Sensation Seeking Scale, Form V, were administered to 97 male and 104 female undergraduate students. The results indicated that, over time, high sensation seekers tend to become involved in more sports than do low sensation seekers, but low sensation seekers tend to remain involved with each sport for longer periods of time than do high sensation seekers. Gender and sensation seeking were found to interact in the choice of sporting activities. Low but generally positive correlations were observed between sensation seeking and participation in risky sports. These data suggest that both the need for new experiences and an attraction to high risk characterize the high sensation seeker 's participation in sporting activities.

Despite improvements in care for patients with cancer, and in their survival rates, it is not clear that best practices are uniformly delivered to patients. We measured the quality of outpatient cancer care, using validated quality measures, in a consortium of thirty-six outpatient oncology practices in Michigan. We discovered that throughout the measurement period, for breast and colorectal cancer care, there was a more than 85 percent rate of adherence to quality care processes. For end-of-life care processes, the adherence rate was 73 percent, and for symptom and toxicity management care processes, adherence was 56 percent. In particular, we found variations in care around the fundamental oncologic task of management of cancer pain. To address quality gaps, we developed interventions to improve adherence to treatment guidelines, improve pain management, and incorporate palliative care into oncology practice. We concluded that statewide consortia that assume much of the cost burden of quality improvement activities can bring together oncology providers and payers to measure quality and design interventions to improve care.

Aim: The aim of the study was to assess the perceived value of genetic testing for congenital deafness in families attending a clinical genetic outpatients department at a children’s hospital. The major testing objective was to provide information regarding deafness etiology, although families were advised that changes in treatment as a result of the test were unlikely. Using a ‘willingness-to-pay’ approach in the form of a questionnaire developed by Ryan et al. [J Med Genet 2003;40:1–5], parents were surveyed for their attitudes and willingness to pay for genetic testing. Results: Forty-nine families provided data for analysis, representing 56% of clinic attendances throughout the period. Most of the parents were themselves unaffected by hearing loss (93%) and none were deaf, although almost a quarter (22%) reported a family member born deaf. Parents considered the major benefit gained from testing was to better achieve clarity of understanding arising from discussion and the possible ascertainment of etiology. The average sum parents were willing to pay for genetic testing was 200 Australian dollars (AUD, 2007) or approximately 123 euros (EUR), ranging from 150 to 295 AUD according to ability to pay (as measured by gross income). However, the amount that even the highest income level were willing to pay underestimated the full economic cost of genetic testing. Conclusion: Genetic testing for deafness is highly valued by affected families despite the current limited overall expectation of definitive genetic diagnosis or changes in treatment. Parents considered the major benefits to be a better understanding of congenital deafness and the potential for assignment of causality.

No abstract

No abstract